Answers are grounded in this paper and cite their sources.
Engineered CAR-T cells show anti-tumor efficacy in humanized mouse models, highlighting resistance to immunological barriers.
Description Chimeric Antigen Receptor (CAR) T cells have induced remarkable clinical responses in patients with hematological cancers. However, CAR-T therapies against solid tumors have not elicited similar outcomes because immunosuppressive barriers in the tumor microenvironment (TME) effectively attenuate anti-tumor activity. Here, we developed a multifaceted approach to engineer allogeneic (‘off-the-shelf’) CAR-T cells resistant to both biochemical (hypoxia-adenosinergic) and immunological (PD-L1 and TGF-β) inhibitory signaling using an adenine base editor and a CRISPR-Cas12b nuclease. The resulting CAR-T product comprised a combination of six gene edits to evade allorejection (B2M, CIITA), prevent graft-versus-host disease (CD3E) and resist biochemical (ADORA2A) and immunological (PDCD1, TGFBR2) negative regulation. This novel combinatorial genetic disruption in CAR-T cells enabled anti-tumor efficacy leading to improved tumor elimination and survival in humanized mouse models recapitulating a human TME. Our unique strategy conferred CAR-T cells resistance to a diverse TME and may unlock the therapeutic potential of CAR-T cells against solid tumors.
No takes yet. Share an insight, caveat, or question.
Stephen Matthew Hatfield (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: